Medical Oncology

KRAS

Questions discussed in this category

What are your top takeaways from ASCO GI 2026?

How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...

4 Answers available

What are your treatment considerations for a patient with stage IVb NSCLC who is KRAS G12C mutated and PD-L1 high (>50%)?

3 Answers available

How do you approach treatment sequencing in KRAS G12C NSCLC?

Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy?

3 Answers available

Are there best practices for managing or mitigating toxicity from sotorasib such as hyperbilirubinemia or edema?

3 Answers available

Papers discussed in this category

Lancet Oncol, 2021 Jan 18

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Future oncology (London, England), 2025 Nov 13

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.

Medical Oncology

KRAS

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology